The effects of symbiotic supplement on complications of type 2 diabetes

The effects of symbiotic supplement containing Bacillus coagulans and fructo oligosaccharide on glycemic index , cardiovascular risk factors and and systemic inflammation in patients with type 2 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190103042220N1

Enrollment

Registered

2019-01-07

Start date

2018-06-05

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: Intervention group will receive 1 sachets contains symbiotic every day for 12 weeks. Intervention 2: Control group: Control group will receive 1 placebo every day f

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Willingness to cooperate and complete informed informed consent form • Patients aged 30-70 years • Body mass index = 35 kg / m2 • haveType 2 diabetes • No history of alcohol or alcohol less than 10 grams Per day in women and less than 20 grams per day in men • no pregnancy and lactation • no thyroid gland disorders • no kidney and inflammatory disease • failure to follow weight loss regimens 6 months before the start of the study • no use Slimming drugs (Orlites, Slim Lists) and fat burners, fiber powder • Non-use of glucocorticoids and non-steroidal anti-inflammatory drugs • no use of insulin

Exclusion criteria

Exclusion criteria: •show complications associated with supplementation• No regular use of supplement• Consume less than 80% of supplements in three months

Design outcomes

Primary

Measure	Time frame
Changes in fasting blood sugare. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Triglyceird level. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Low-density lipoprotein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;High-density lipoprotein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Serum insulin level. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;High-sensitive C-reactive protein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.	—

Measure

Time frame

Changes in fasting blood sugare. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Triglyceird level. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Low-density lipoprotein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;High-density lipoprotein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;Serum insulin level. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.;High-sensitive C-reactive protein. Timepoint: At the baseline of intervention and at the end of study. Method of measurement: Enzymatic methods using kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolbon Sohrab

Shahid Beheshti University of Medical Sciences

golbonsohrab@yahoo.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026